Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 1995;76:310-316

This Article
Right arrow Abstract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smirnov, S. V.
Right arrow Articles by Aaronson, P. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smirnov, S. V.
Right arrow Articles by Aaronson, P. I.
(Circulation Research. 1995;76:310-316.)
© 1995 American Heart Association, Inc.


Articles

Inhibition of Vascular Smooth Muscle Cell K+ Currents by Tyrosine Kinase Inhibitors Genistein and ST 638

Sergey V. Smirnov, Philip I. Aaronson

From the Department of Pharmacology, United Medical and Dental Schools of Guy's and St Thomas's Hospitals, London, England.

Correspondence to P.I. Aaronson, Department of Pharmacology, United Medical and Dental Schools of Guy's and St Thomas's Hospitals, St Thomas's Campus, Lambeth Palace Rd, London SE1 7EH, England.


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMaterials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Abstract The whole-cell patch-clamp technique was used to characterize the effects of several tyrosine kinase inhibitors on the voltage-gated K+ current (IK) in rat and rabbit pulmonary artery cells. IK was blocked in a dose-dependent manner by genistein (20 to 100 µmol/L) and ST 638 (0.5 to 40 µmol/L) but not by the inactive genistein analogue diadzein (100 µmol/L). This inhibition was not significantly altered when ATP was excluded from the patch pipette or when it was replaced by the poor tyrosine kinase substrate ATP-{gamma}-S. The inhibition was also unaffected by inclusion of the tyrosine phosphatase inhibitor orthovanadate in either the bath (0.5 mmol/L) or pipette (0.2 mmol/L) solutions. In the rat, IK ordinarily inactivated negligibly over 300 ms. In the presence of 10 µmol/L ST 638, however, IK reached a peak {approx}5 ms after depolarization (to +60 mV) and then decayed markedly. In the rabbit, IK demonstrated a prominent rapidly decaying initial component that was only slightly inhibited by ST 638, which preferentially blocked the sustained current; genistein showed the opposite selectivity. These observations indicated that IK blockade by genistein and ST 638 was not mediated by an inhibition of tyrosine kinase activity and further suggested that in both types of cells genistein and ST 638 preferentially blocked rapidly and slowly inactivating components of IK, respectively.


Key Words: pulmonary artery • vascular smooth muscle • ion channels • K+ channels • protein tyrosine kinase inhibitors


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMaterials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Although protein tyrosine kinases (PTKs) are most notable for their role in regulating long-term processes such as cellular growth, division, and metabolism,1 2 tyrosine kinases can also mediate rapidly occurring events, such as phosphatidylinositol turnover3 and vascular smooth muscle contraction.4 Pharmacological inhibitors of PTKs (PTKIs) inhibit contractions induced by the stimulation of G protein–linked receptors in vascular and intestinal smooth muscle,5 6 and it has recently been proposed that an intermediary nonreceptor tyrosine kinase may mediate contractions elicited by many types of agonists.6 In vascular smooth muscle cells of the rabbit ear artery, several PTKIs diminished the Ca2+ current, implying the existence of tonic regulation of this current by a tyrosine kinase.7 In the present study, we have examined the effect of several PTKIs on the voltage-gated K+ current (IK) in rat8 9 and rabbit10 pulmonary artery cells to determine whether this current might also be regulated by a tyrosine kinase. Our results indicate that although the PTKIs genistein and ST 638 potently and reversibly inhibit the voltage-gated IK in these smooth muscle cells, these responses do not appear to involve PTK inhibition. Our data also suggest that genistein and ST 638 are selective for different IKs.


*    Materials and Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Materials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Male Wistar rats (250 to 300 g) were killed by cervical dislocation, and male New Zealand White Rabbits were killed by injection of 80 mg/kg phenobarbitone into the ear artery. After excision of the heart and lungs, pulmonary arteries were rapidly dissected out. Single vascular smooth muscle cells were enzymatically isolated, as previously described for the rat8 9 and the rabbit,10 and conventional whole-cell patch-clamp recordings were made, as described in detail previously.8 9 The control patch pipette solution contained (mmol/L) KCl 110, MgCl2 0.5, Na2ATP 5, HEPES 10, EGTA 10, and CaCl2 0.5 (pKCa=8 nmol/L); the solution was set to pH 7.2 with KOH. The bathing solution contained (mmol/L) NaCl 130, KCl 5, MgCl2 1.2, CaCl2 1.5, HEPES 10, and glucose 10, pH 7.2 to 7.4. Tetraethylammonium chloride (10 mmol/L), which we have previously shown produces a selective abolition of the Ca2+-activated IK in these cells,8 9 was also added to all bath solutions. All experiments were carried out at room temperature. In some cases, cells were preincubated in glucose-free or orthovanadate-containing solutions at 4°C before the experiments (see "Results"). Genistein, diadzein, and tyrphostins 1 and 23 (all from Calbiochem) and ST 638 were dissolved in dimethyl sulfoxide and stored at -20°C until just before use. ST 638 is a 4-hydroxycinnamamide derivative that inhibits PTK activity in vitro by competing with the substrate protein for the PTK.11 12 13 Genistein is an isoflavone derivative that inhibits PTK activity by competing with ATP for its binding to PTKs.14 15 Means were compared by using Student's paired or unpaired t test; differences were deemed significant at P<.05 (unless otherwise stated). All data are presented as mean±SD.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
*Results
down arrowDiscussion
down arrowReferences
 
Fig 1Down illustrates that both 10 µmol/L ST 638 (Fig 1aDown and 1bDown) and 100 µmol/L genistein (Fig 1cDown and 1dDown) rapidly and reversibly blocked the tetraethylammonium-insensitive voltage-gated IK in rat pulmonary artery smooth muscle cells. The current amplitude measured at 100 ms was significantly reduced to 0.09±0.03 (n=14) of control by ST 638. IK normally showed negligible inactivation over 300 ms; however, in the presence of ST 638, the current decayed rapidly (Fig 1bDown). Genistein reduced the current amplitude to 0.47±0.13 (n=15) of control. Although genistein had no consistent effect on the decay of IK, it did significantly slow its activation (Fig 1dDown). The average time to half-maximal activation of IK increased by about two times, from 3.6±0.8 ms (n=15) in the control bathing solution to 6.7±2.2 ms (n=13) in the presence of 100 µmol/L genistein (P<.0001). Diadzein, an analogue of genistein, which is inactive as a PTKI,16 had no effect on IK at a concentration of 100 µmol/L (Fig 1cDown); the amplitude of IK in diadzein was 0.96±0.03 (n=4) of the control. Tyrphostin 23, a member of a different chemical family of PTKIs, also had no effect on the amplitude of IK (0.95±0.01, n=5); however, a minor inhibition was observed with its analogue tyrphostin 1 (0.86±0.06, n=4).



View larger version (22K):
[in this window]
[in a new window]
 
Figure 1. Time courses (a and c) and tracings (b and d) showing the effects of ST 638, genistein (GEN), and diadzein (DIAD) on K+ current (IK) in rat pulmonary artery cells. a, The effect of ST 638 (10 µmol/L) on IK amplitude measured at the end of 300-ms steps to +60 mV, applied every 10 s. b, IK before (1) and during (2) the bath application of ST 638, at times indicated in panel a. c, The effect of GEN and DIAD (both 100 µmol/L) on IK amplitude, measured at 100 ms. d, Effect of genistein on IK kinetics. Arrows indicate the zero current level.

If these inhibitory effects of genistein and ST 638 were due to a PTKI-mediated decrease in tyrosine phosphorylation of the IK channel(s), the rapid onset and offset of the responses to these drugs would imply that basal turnover of phosphorylation must also be rapid. If so, removal of cellular ATP should reduce the response to the drugs (by reducing basal tyrosine phosphorylation and therefore the capacity of IK to be inhibited by dephosphorylation) and would block rephosphorylation-mediated recovery of the current after drug removal. However, the TableDown shows that the exclusion of ATP from the patch pipette or its replacement with ATP-{gamma}-S, an ATP analogue that is a poor substrate for PTKs17 and should thus competitively block their utilization of any residual cellular ATP, had no effect on the ability of genistein to block IK. Similar results were obtained when we used ATP-free and ATP-{gamma}-S-containing pipette solutions under glucose-free conditions, where cells had also been preincubated without glucose for 95 to 330 minutes. Current blockade by ST 638 was also generally unaffected by these maneuvers. There was some attenuation of the ST 638–mediated current blockade in 0.5 mmol/L ATP-{gamma}-S in the presence of glucose and in ATP-free conditions in the absence of glucose, but these effects were very small (7% and 4% reduction of the response to ST 638, respectively) and are unlikely to be of mechanistic significance. The recovery of IK on drug removal was also not significantly altered by ATP exclusion (not shown).


View this table:
[in this window]
[in a new window]
 
Table 1. Effect of Exclusion of ATP From Pipette Solution on K+ Current Blockade by ST 638 and Genistein

Inhibition of phosphatase-mediated tyrosine dephosphorylation would also be expected to block current inhibition by the PTKIs, since dephosphorylation in the presence of the PTKIs would require ongoing phosphatase activity. However, Fig 2Down shows that orthovanadate, which blocks tyrosine phosphatases,18 19 20 did not significantly affect the responses to ST 638 (Fig 2aDown and 2cDown) and genistein (Fig 2bDown and 2dDown). This was true whether cells were incubated in 0.5 mmol/L extracellular orthovanadate before (for 75 to 200 minutes) and during experiments (Fig 2aDown and 2bDown) or whether orthovanadate was included in the pipette solution at a concentration of 0.2 mmol/L (Fig 2cDown and 2dDown). The recovery of IK from blockade was also not significantly affected by orthovanadate (not shown).



View larger version (29K):
[in this window]
[in a new window]
 
Figure 2. Bar graphs showing lack of effect of orthovanadate (VAN) on inhibition of K+ current (IK) (measured after 100-ms depolarization to +60 mV) by ST 638 or genistein (GEN). a and b, Fraction of IK remaining after exposure to 4 or 10 µmol/L ST 638 (a) or 100 µmol/L GEN (b) in the presence (hatched bars) or absence (open bars) of 0.5 mmol/L VAN in the external solution. c and d, The effects of 10 µmol/L ST 638 (c) and 100 µmol/L GEN (d) in the presence (hatched bars) and absence (open bars) of 0.2 mmol/L VAN in the patch pipette solution. The number of cells in each group studied is shown inside the bars.

Figs 3Down and 4Down illustrate additional aspects of the blockade of IK by ST 638. To define the potential dependence of the effect of ST 638, cells were held at -60 mV and depolarized for 100 ms at a frequency of 0.1 Hz, with each successive depolarization being incremented by +10 mV. The currents elicited at -20, 0, +20, and +40 mV in the absence and presence of 10 µmol/L ST 638 are shown superimposed in Fig 3aDown. The current decayed quickly in the presence of ST 638 over a range of membrane potentials. This decay was well fitted by a single monoexponential function with time constants of 33.5±7.3 ms at 0 mV, 25±4 ms at +20 mV, 22.9±6.1 ms at +40 mV, and 21.2±7.3 ms at +60 mV (n=5 for 0 mV, n=6 for other potentials). The amplitudes of IK measured at the end of each depolarizing step in the presence and absence of ST 638 are shown in the current-voltage (I-V) plot, as is the amplitude measured at the peak of the current in the presence of ST 638 (Fig 3bDown). The I-V relation indicates that the inhibition of IK by ST 638 showed little dependence on the magnitude of depolarization. Fig 3cDown shows the effects of three concentrations of ST 638 on IK. It is apparent that at each concentration of the drug, the extent of current inhibition increased with time during depolarization. As shown in Fig 3dDown, this was manifested as a significant difference between the apparent potency of ST 638 when its inhibition of the current was measured 4 to 6 ms after the initiation of depolarization (when the current resistant to 10 µmol/L ST 638 reached its peak) and when it was measured 100 ms into the depolarization. The IC50 for the inhibition of the IK measured at the end of a 100 ms step to +60 mV was 2 µmol/L, which is 4.3-fold less than the IC50 obtained if the current was measured at 4 to 6 ms.



View larger version (20K):
[in this window]
[in a new window]
 
Figure 3. Inhibitory effect of ST 638 on K+ current (IK) in rat pulmonary artery cells. a, A family of IKs recorded at the test potentials indicated in control solution (upper tracings) and in the presence of 10 µmol/L ST 638 (lower tracings). Arrows indicate the zero current level. b, Graph showing current-voltage relations measured at the end of 100-ms pulse (circles) and at the time of the peak of ST 638–resistant current (squares) in the absence (open symbols) or presence of 10 µmol/L ST 638 (filled symbols). Vm indicates membrane voltage. c, Tracings showing effect on IK of 0.5, 2, and 10 µmol/L ST 638. Current was elicited by a 100-ms depolarization to +60 mV. d, Graph showing inhibition of IK measured at the time when the current in 10 µmol/L ST 638 was at its peak (4 to 6 ms) and also at 100-ms depolarization in 3 to 15 cells (filled and empty circles, respectively; refer to panel c). These data were fit by the Langmuir function. The IC50 was 8.6 µmol/L for the block of the early current and 2 µmol/L for the current at 100 ms. The Hill coefficients were 1.3 and 1.8, respectively. Holding potential was -60 mV.



View larger version (21K):
[in this window]
[in a new window]
 
Figure 4. Use dependence and voltage dependence of the effect of ST 638 on K+ current (IK). a, IK measured during trains of 20 voltage steps to +60 mV was applied at a frequency of 0.5 Hz in the absence and presence (shown by horizontal bar) of 2 µmol/L ST 638. Current amplitude was measured 100 ms after the initiation of depolarization. The interval between trains was 1 minute. b, Current amplitude normalized to that measured during the first pulse in the train was plotted against time in the absence (open circles) and in the presence of ST 638 (filled circles). Graph shows average data obtained from four pulmonary artery cells. c, Graph shows availability for IK recorded from a pulmonary arterial cell in control solution (open circles) and in the presence of 2 µmol/L ST 638 (triangles) and for the ST 638–resistant current in the presence of 10 µmol/L ST 638 (filled circles). Availability was recorded by using 10-s conditioning depolarization between -90 or -120 mV and +30 mV and a test pulse to +60 mV. Current amplitude was measured 100 ms into the test pulse and normalized to that observed after the conditioning step to -90 mV in control and 2 µmol/L ST 638. In 10 µmol/L ST 638, the current was measured at its peak and normalized to that after the conditioning pulse to -120 mV. Solid lines were drawn according to the Boltzmann function with a potential of half-inactivation (V0.5) equal to -25.1, -25.7, and -55.6 mV and slope factors of 6.8, 7.1, and 19.1 mV in the control condition and in the presence of 2 and 10 µmol/L ST 638, respectively. Dashed lines show V0.5 levels.

One possible explanation for this time-dependent increase in current inhibition by ST 638 is that the drug has a use-dependent effect. To examine for this, cells were subjected to a train of 20 depolarizing steps of 100-ms duration applied at a frequency of 0.5 Hz. Application of this train led to a progressive diminution of IK under control conditions, possibly due to accumulation of current inactivation (Fig 4aUp). The amplitude of IK was completely restored during a subsequent 1-minute stimulation-free interval, and a second pulse train caused a similar diminution of IK. When 2 µmol/L ST 638 was then added at the beginning of a second 1-minute rest period, a typical inhibition of the current amplitude in response to the first pulse was observed. The current then declined further during the rapid pulse train (Fig 4aUp). However, the extent and time course of this decline were not different from those observed in the absence of drug (Fig 4bUp), thus suggesting that ST 638 was not having a use-dependent effect. Similar experiments carried out in two cells using a higher frequency of test pulses (20 applied at 1 Hz) also revealed no apparent use-dependent effect (not shown).

To investigate the effect of ST 638 on the potential dependence of IK inactivation, the availability of IK was measured in the absence and presence of drug, using a 100-ms test pulse to +60 mV, which followed a 10-s step to a conditioning potential between -90 or -120 and +30 mV. The amplitude of IK was measured at the end of the test pulse and normalized to that measured after the conditioning step to -90 mV. Fig 4cUp illustrates a typical experiment where the availabilities of IK in the control solution (open circles) and in the presence of 2 µmol/L ST 638 (triangles) were compared. This concentration of the drug, which inhibited IK by {approx}50%, produced no apparent shift in its availability. In a number of similar experiments, the potential of half-inactivation (V0.5) was -23.9±6.8 mV (n=7) in controls and -29.6±6.5 mV (n=6) in 2 µmol/L ST 638; the slope factors (k) were 7.8±2.4 mV and 7.4±2 mV, respectively. Fig 4cUp also shows that in 10 µmol/L ST 638, the inactivation of the transient current (at its peak, 4 to 6 ms after depolarization was initiated) occurred over a much more negative potential range than did that of the control current. In this case, V0.5 was -58.2±7.3 mV, and k was 18.7±2.3 mV in five cells studied (P<.001 compared with control or 2-µmol/L values).

Fig 5aDown illustrates the effect of genistein (100 µmol/L) on IK at several test potentials; the resulting I-V relation is illustrated in Fig 5bDown. No obvious effect of potential on IK inhibition was apparent. The inhibition of IK and of the ST 638–resistant current by 20 and 100 µmol/L genistein is shown in Fig 5cDown and 5dDown, respectively. It was apparent that genistein was a more effective blocker of the ST 638–resistant current than it was of IK itself. This difference is more easily visualized when the data are normalized, as shown in Fig 5eDown. It is clear, for example, that 20 µmol/L genistein blocked the ST 638–resistant current at least as much as 100 µmol/L genistein blocked IK itself.



View larger version (22K):
[in this window]
[in a new window]
 
Figure 5. Tracings (a, c, and d) and graphs (b and e) showing the effect of genistein on K+ current (IK) in rat pulmonary arterial cells. a, A family of IKs recorded at -20, 0, 20, and 40 mV in the absence (upper tracings) and presence (lower tracings) of 100 µmol/L genistein. Arrows indicate the zero current level. b, Current-voltage relation of the currents shown in panel a. Open and filled circles show the current amplitude measured at 100 ms in the control solution and in the presence of the drug, respectively. Vm indicates membrane voltage. c, The control current (1) and the current in 20 (2) or 100 (3) µmol/L genistein. d, IK in the presence of 10 µmol/L ST 638 (1) and in the additional presence of 20 (2) or 100 (3) µmol/L genistein. Vertical bars in panels c and d are equal to 140 and 220 pA, respectively. Panels c and d were recorded from two pulmonary arterial cells. e, The block of the control (open bars) and ST 638–resistant (solid bars) current by 20 and 100 µmol/L genistein. The control current was measured 100 ms after depolarization, and the ST 638–resistant current was measured as the difference between the peak current early in depolarization and the current remaining after 100 ms. The number of cells in each group studied is shown inside the bars. Holding potential was -60 mV.

Fig 6Down shows the effects of ST 638 and genistein in another type of smooth muscle cell, that of the rabbit pulmonary artery. Here, IK has a particularly prominent A-like component.10 Panels a and b demonstrate that this rapidly decaying current component was almost insensitive to 10 µmol/L ST 638, which, however, blocked most of the current measured at 100 ms. Conversely, 100 µmol/L genistein blocked most of the A-like current, while having little effect on the current measured at 100 ms (Fig 6cDown and 6dDown).



View larger version (23K):
[in this window]
[in a new window]
 
Figure 6. Tracings (a and c) and bar graphs (b and d) showing effects of 10 µmol/L ST 638 and 100 µmol/L genistein on K+ current (IK) in rabbit pulmonary artery smooth muscle cells. a, Block by ST 638 of IK in one cell. Arrows indicate the zero current level. b, Effect of ST 638 on the current measured at the time when the rapidly inactivating component was at its peak (empty bar) and 100 ms after depolarization (hatched bar) (P<.0001). The number of cells in each group studied is shown inside the bars. c, Block by genistein of IK in the same cell as shown in panel a. d, Effect of genistein on the peak (open bar) and sustained (hatched bar) current measured as described for panel b (P<.0001).


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowResults
*Discussion
down arrowReferences
 
Although many PTKs exist as plasmalemmal receptors that are activated directly by the binding of growth factors, there are a large number of types of nonreceptor PTKs that may also serve as key intermediates in mediating signal transduction via cytokine and G protein–linked receptors.3 21 A number of recent reports have suggested that contractions of smooth muscle elicited by agonists such as angiotensin II and noradrenaline, which stimulate G protein–linked receptors, are mediated in part by as-yet-unidentified PTKs.5 6 It is also the case that orthovanadate, which blocks tyrosine phosphatases, induces smooth muscle contraction in parallel with tyrosine phosphorylation of as-yet-unidentified cellular proteins20 and that several growth factors that are known to bind to receptor tyrosine kinases cause tension development.4 It is noteworthy that evidence for the role of putative tyrosine kinases in the contractile responses of smooth muscle to G protein–linked receptor stimulation and to orthovanadate rests largely on the finding that such responses are blocked by pharmacological PTKIs, especially genistein.6 20

Our results indicate, however, that genistein and ST 638 both block IK in concentration ranges similar to those used to inhibit PTKs,11 12 13 14 15 16 although their effects on IK are not mediated by PTK inhibition. Therefore, it appears that two structurally dissimilar PTKIs, which act via different mechanisms to inhibit PTKs, both share the ability to block voltage-gated K+ channels in vascular smooth muscle cells. It has previously been shown that genistein and tyrphostins 1 and 23 block the L-type Ca2+ currents in vascular smooth muscle cells.7 This effect was not shared by diadzein, which is often used with genistein as a control, since it is structurally similar but inactive as a PTKI.16 These data therefore suggested that the effects of these agents were due to some type of effect on a PTK. However, our present results show that diadzein is also ineffective in mimicking an action of genistein that is not mediated by inhibition of a PTK. Therefore, it appears that genistein and ST 638 are somewhat nonselective in their actions and that diadzein may not always be an appropriate control agent. Observations that tyrosine kinase inhibitors, including genistein, cause a selective suppression of agonist- but not depolarization-induced contractions underpin the emerging concept that tyrosine kinases may play an important role in excitation-contraction coupling in vascular and visceral smooth muscle.5 6 However, the present results indicate that observations made in isolated tissues may reflect effects that are independent of tyrosine kinase inhibition. The contribution of such additional actions of tyrosine kinase inhibitors to the inhibition of agonist-mediated contractions remains an important subject for future investigation.

ST 638 not only reduced the amplitude of IK but caused it to decay much more rapidly than was observed in the absence of drug. One explanation for this might be that ST 638 was producing some type of use-dependent block, possibly by interacting preferentially with open or inactivated states of the channel mediating IK. We did not observe, however, any evidence for use dependence when cells were stimulated at high frequencies, although we cannot exclude entirely the possibility of a fast open-channel blockade. There was also no indication that the increased channel opening (and likely inactivation) associated with progressive depolarization promoted the inhibition of IK.

A second explanation for the effects of ST 638, which would explain all of the results obtained in the rat pulmonary artery cells, is that IK is composed of two components that are differentially blocked by ST 638. One is a relatively small A-like current that inactivates rapidly during depolarization and is also inactivated over a fairly negative range of conditioning potentials, as it was described in other types of smooth muscle cells.10 22 23 24 25 This component would be relatively insensitive to ST 638. A second, larger component would be more sensitive to ST 638 and would give rise to a current that inactivated more slowly during depolarization and over a more positive range of conditioning potentials. This arrangement would explain the apparent lower potency of ST 638 against the current measured 5 ms after the initiation of depolarization compared with that measured after 100 ms. This assumption would also be consistent with the observations that the rapidly decaying current observed in the presence of 10 µmol/L ST 638 inactivated over a more negative potential range than did the current in the absence of drug, even though a concentration of drug that inhibited the current by 50% (2 µmol/L) had no effect on the availability of the current measured at 100 ms. The latter observation suggests that ST 638 itself, at a concentration sufficient to markedly diminish the current, did not affect its inactivation-potential relation. Conversely, in the former case, the availability of the ST 638–resistant current would mostly reflect that of the small rapidly inactivating component of current.

The response of the rabbit pulmonary artery cells to ST 638 is also consistent with this model. These cells have previously been shown to demonstrate a prominent A-like current that inactivates over a negative potential range.10 The rapidly decaying component of current in these cells was only slightly blocked by ST 638, whereas the current measured at 100 ms was very markedly reduced.

If this model of two components of current is correct, it also suggests that genistein might have a greater action on the A-like current than on the slowly inactivating component of current. This possibility is supported by the finding that genistein slowed current activation (consistent with the blockade of a rapidly activating and inactivating component of current) and also by our observation that genistein had a greater effect on the ST 638–resistant current than on IK measured 100 ms after depolarization, at which time IK should consist almost entirely of the slowly inactivating component. The effect of genistein on the K+ current in the rabbit pulmonary artery cells, in which it essentially abolished the A-like component of current yet had little effect on the current measured at 100 ms, provides additional support for this concept.

Although our present observations appear to be entirely consistent with this model, they do not rule out the possibility that these compounds are interacting differentially with one type of K+ channel via mechanisms not considered above. Confirmation of the mechanisms of action of these agents must therefore await a more detailed scrutiny, possibly at the single-channel level.


*    Acknowledgments
 
We thank the British Heart Foundation, the Wellcome Trust, and the Special Trustees for St Thomas' Hospital for financial support and Dr O. Osipenko for the isolation of rabbit pulmonary artery cells. ST 638 was kindly supplied by T. Shiraishi of the Kanegafuchi Chemical Industry Co, Japan.

Received June 27, 1994; accepted October 18, 1994.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowResults
up arrowDiscussion
*References
 

  1. Meager A. Cytokines. Milton Keynes: Open University Press; 1990.
  2. Fantl WJ, Johnson DE, Williams LT. Signalling by receptor tyrosine kinases. Annu Rev Biochem. 1993;62:453-481. [Medline] [Order article via Infotrieve]
  3. Kuruvilla A, Putcha G, Poulos E, Shearer WT. Tyrosine phosphorylation of phospholipase C concomitant with its activation by platelet activating factor in a human B cell line. J Immunol. 1993;151:637-648. [Abstract]
  4. Berk BC, Alexander RW, Brock TA, Gimbrone MA, Webb C. Vasoconstriction: a new activity for platelet-derived growth factor. Science. 1986;232:87-90. [Abstract/Free Full Text]
  5. Di Salvo J, Steusloff A, Semenchuk L, Satoh S, Kohlquist K, Pfitzer G. Tyrosine kinase inhibitors suppress agonist-induced contraction in smooth muscle. Biochem Biophys Res Commun. 1993;190:968-974. [Medline] [Order article via Infotrieve]
  6. Hollenberg MD. Tyrosine kinase pathways and the regulation of smooth muscle contractility. Trends Pharmacol Sci. 1994;15:108-114. [Medline] [Order article via Infotrieve]
  7. Wijetunge S, Aalkjaer C, Schachter M, Hughes AD. Tyrosine kinase inhibitors block calcium channel currents in vascular smooth muscle cells. Biochem Biophys Res Commun. 1992;189:1620-1623. [Medline] [Order article via Infotrieve]
  8. Smirnov SV, Robertson TP, Ward JPT, Aaronson PI. Chronic hypoxia is associated with reduced delayed rectifier K+ current in rat pulmonary artery muscle cells. Am J Physiol. 1994;266:H365-H370. [Abstract/Free Full Text]
  9. Smirnov SV, Aaronson PI. Alteration of the transmembrane K+ gradient during development of delayed rectifier in isolated rat pulmonary arterial cells. J Gen Physiol. 1994;104:241-264. [Abstract/Free Full Text]
  10. Clapp LH, Gurney AM. Outward currents in rabbit pulmonary artery cells dissociated with a new technique. Exp Physiol. 1991;76:677-693. [Abstract]
  11. Shiraishi T, Domoto T, Imai N, Shimada Y, Watanabe K. Specific inhibitors of tyrosine-specific protein kinase, synthetic 4-hydroxycinnamamide derivatives. Biochem Biophys Res Commun. 1987;147:322-328. [Medline] [Order article via Infotrieve]
  12. Shiraishi T, Owada MK, Tatsuka M, Yamashita T, Watanabe K, Kakunaga T. Specific inhibitors of tyrosine-specific protein kinases: properties of 4-hydroxycinnamamide derivatives in vitro. Cancer Res. 1989;49:2374-2378. [Abstract/Free Full Text]
  13. Akimaru K, Utsumi T, Sato EF, Klostergaard J, Inoue M, Utsumi K. Role of tyrosyl phosphorylation in neutrophil priming by tumor necrosis factor-alpha and granulocyte colony stimulating factor. Arch Biochem Biophys. 1992;298:703-709. [Medline] [Order article via Infotrieve]
  14. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M, Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem. 1987;262:5592-5595. [Abstract/Free Full Text]
  15. Gaudette DC, Holub BJ. Effect of genistein, a tyrosine kinase inhibitor, on U46619-induced phosphoinositide phosphorylation in human platelets. Biochem Biophys Res Commun. 1990;170:238-242.[Medline] [Order article via Infotrieve]
  16. Peterson G, Barnes S. Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate. 1993;22:335-345. [Medline] [Order article via Infotrieve]
  17. Srivastava AK, Chiasson JL. Comparative characterization of receptor and non-receptor associated protein tyrosine kinases. Biochim Biophys Acta. 1989;996:13-18. [Medline] [Order article via Infotrieve]
  18. Swarup G, Cohen S, Garbers DL. Inhibition of membrane phosphotyrosil-protein phosphatase activity by vanadate. Biochem Biophys Res Commun. 1982;107:1104-1109. [Medline] [Order article via Infotrieve]
  19. Brown DJ, Gordon JA. The stimulation of pp60v-src kinase activity by vanadate in intact cells accompanies a new phosphorylation state of the enzyme. J Biol Chem. 1984;259:9580-9586. [Abstract/Free Full Text]
  20. Di Salvo J, Semenchuk LA, Lauer J. Vanadate-induced contraction of smooth muscle and enhanced protein tyrosine phosphorylation. Arch Biochem Biophys. 1993;304:386-391.[Medline] [Order article via Infotrieve]
  21. Mustelin T, Burn P. Regulation of src family tyrosine kinases in lymphocytes. Trends Biol Sci. 1993;18:215-220.
  22. Beech DJ, Bolton TB. A voltage-dependent outward current with fast kinetics in single smooth muscle cells isolated from rabbit portal vein. J Physiol (Lond). 1989;412:397-414. [Abstract/Free Full Text]
  23. Imaizumi Y, Muraki K, Watanabe M. Characteristics of transient outward currents in single smooth muscle cells from the ureter of the guinea-pig. J Physiol (Lond). 1990;427:301-324. [Abstract/Free Full Text]
  24. Smirnov SV, Zholos AV, Shuba MF. A potential-dependent fast outward current in single smooth muscle cells isolated from the newborn rat ileum. J Physiol (Lond). 1992;454:573-589. [Abstract/Free Full Text]
  25. Smirnov SV, Aaronson PI. Ca2+-activated and voltage-gated K+ currents in smooth muscle cells isolated from human mesenteric arteries. J Physiol (Lond). 1992;457:431-454. [Abstract/Free Full Text]



This article has been cited by other articles:


Home page
Circ. Res.Home page
A. Cogolludo, L. Moreno, F. Lodi, G. Frazziano, L. Cobeno, J. Tamargo, and F. Perez-Vizcaino
Serotonin Inhibits Voltage-Gated K+ Currents in Pulmonary Artery Smooth Muscle Cells: Role of 5-HT2A Receptors, Caveolin-1, and KV1.5 Channel Internalization
Circ. Res., April 14, 2006; 98(7): 931 - 938.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
A. E. Belevych, S. Warrier, and R. D. Harvey
Genistein Inhibits Cardiac L-Type Ca2+ Channel Activity by a Tyrosine Kinase-Independent Mechanism
Mol. Pharmacol., September 1, 2002; 62(3): 554 - 565.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. J. Davis, X. Wu, T. R. Nurkiewicz, J. Kawasaki, P. Gui, M. A. Hill, and E. Wilson
Regulation of ion channels by protein tyrosine phosphorylation
Am J Physiol Heart Circ Physiol, November 1, 2001; 281(5): H1835 - H1862.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
J. H. Jhamandas, C. Cho, B. Jassar, K. Harris, D. MacTavish, and J. Easaw
Cellular Mechanisms for Amyloid {beta}-Protein Activation of Rat Cholinergic Basal Forebrain Neurons
J Neurophysiol, September 1, 2001; 86(3): 1312 - 1320.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
E. Middleton Jr., C. Kandaswami, and T. C. Theoharides
The Effects of Plant Flavonoids on Mammalian Cells:Implications for Inflammation, Heart Disease, and Cancer
Pharmacol. Rev., December 1, 2000; 52(4): 673 - 751.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
C. A. Goddard, M. J. Evans, and W. H. Colledge
Genistein activates CFTR-mediated Cl- secretion in the murine trachea and colon
Am J Physiol Cell Physiol, August 1, 2000; 279(2): C383 - C392.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
C. Xu, Y. Lu, G. Tang, and R. Wang
Expression of voltage-dependent K+ channel genes in mesenteric artery smooth muscle cells
Am J Physiol Gastrointest Liver Physiol, November 1, 1999; 277(5): G1055 - G1063.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. G. Wang and S. L. Lipsius
Genistein elicits biphasic effects on L-type Ca2+ current in feline atrial myocytes
Am J Physiol Heart Circ Physiol, July 1, 1998; 275(1): H204 - H212.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
D. A. Fadool, T. C. Holmes, K. Berman, D. Dagan, and I. B. Levitan
Tyrosine Phosphorylation Modulates Current Amplitude and Kinetics of a Neuronal Voltage-Gated Potassium Channel
J Neurophysiol, September 1, 1997; 78(3): 1563 - 1573.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
H. Karaki, H. Ozaki, M. Hori, M. Mitsui-Saito, K.-I. Amano, K.-I. Harada, S. Miyamoto, H. Nakazawa, K.-J. Won, and K. Sato
Calcium Movements, Distribution, and Functions in Smooth Muscle
Pharmacol. Rev., June 1, 1997; 49(2): 157 - 230.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
X. Wu, G. E. Davis, G. A. Meininger, E. Wilson, and M. J. Davis
Regulation of the L-type Calcium Channel by alpha 5beta 1 Integrin Requires Signaling between Focal Adhesion Proteins
J. Biol. Chem., August 3, 2001; 276(32): 30285 - 30292.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
B. H. Choi, J.-S. Choi, D.-J. Rhie, S. H. Yoon, D. S. Min, Y.-H. Jo, M.-S. Kim, and S. J. Hahn
Direct inhibition of the cloned Kv1.5 channel by AG-1478, a tyrosine kinase inhibitor
Am J Physiol Cell Physiol, June 1, 2002; 282(6): C1461 - C1468.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smirnov, S. V.
Right arrow Articles by Aaronson, P. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smirnov, S. V.
Right arrow Articles by Aaronson, P. I.